NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks

SOUTH SAN FRANCISCO, Calif., April 14, 2018 /PRNewswire/ — NGM Bio, a leading biotech company developing a portfolio of clinical-stage product candidates that modulate novel or previously intractable targets implicated in metabolic and other serious diseases, today announced data from a…